Fangchinoline is primarily studied for its potential in cancer treatment due to its ability to inhibit tumor cell proliferation and induce apoptosis in various cancer cell lines. It shows promise in suppressing the growth of drug-resistant cancer cells, making it a candidate for overcoming chemotherapy resistance. Additionally, fangchinoline exhibits anti-inflammatory and immunomodulatory effects, which are being explored in the context of autoimmune diseases and chronic inflammation. Research also indicates antiviral activity, particularly against certain enveloped viruses, suggesting possible use in antiviral therapies. Its cardiovascular effects, such as lowering blood pressure and reducing cardiac hypertrophy, are under investigation for managing heart-related conditions. Most applications remain in preclinical stages, with ongoing studies to evaluate efficacy and safety.